Autologous bone graft material
AssigneeDePuy Spine, Inc.
InventorsSudhakar Kadiyala, Scott Bruder
Life of this patent
Estimating the term…
Abstract
This invention relates to a musculoskeletogenic MSG graft composite made from whole bone marrow aspirate BMA having native levels of musculoskeletal progenitor cells MSPCs, comprising: a) a suspension of fractionated BMA comprising: i) MSPCs present at a level greater than their native level in whole BMA, and ii) red blood cells RBCs present at a level less than their native level in whole BMA, and b) a porous sterile matrix having an average pore size of at least 20 μm.
Claims8
A musculoskeletogenic (MSG) graft composite made from whole bone marrow aspirate (BMA) having a native level of musculoskeletal progenitor cells (MSPCs), comprising:
- a) a porous matrix having an average pore size of at least 20 μm,
- b) a first clot material present within the interstices of the pores,
- c) MSPCs, and
- d) an additional MSG supplement,
- wherein the MSPCs are present predominantly within the clot material, and
- wherein the MSG supplement is present predominantly bound to the surface of the matrix.
A musculoskeletogenic (MSG) graft composite made from whole bone marrow aspirate (BMA) having a native level of musculoskeletal progenitor cells (MSPCs), comprising:
- a) a porous matrix having an average pore size of at least 20 μm,
- b) a first clot material present within the interstices of the pores,
- c) MSPCs, and
- d) an MSG supplement,
- wherein the MSG supplement is platelets,
- wherein the MSPCs are present predominantly within the clot material, and
- wherein the MSG supplement is present predominantly bound to the surface of the matrix.
A musculoskeletogenic (MSG) graft composite made from whole bone marrow aspirate (BMA) having a native level of musculoskeletal progenitor cells (MSPCs), comprising:
- a) a porous matrix having an average pore size of at least 20 μm,
- b) a first clot material present within the interstices of the pores,
- c) an MSG supplement,
- wherein the first clot material is BMA from which MSPCs have been removed, and
- wherein the MSG supplement is present predominantly bound to the surface of the matrix.
Dependencies are inferred from the claim text.